CrossRefPubMed 27. Egan BJ, O’Connor HJ, O’Morain CA: What is new in the management of Helicobacter pylori? Ir J Med Sci 2008,177(3):185–188.CrossRefPubMed 28. Selgrad M, Malfertheiner P: New strategies for Helicobacter pylori eradication. Curr Opin Pharmacol 2008,8(5):593–597.CrossRefPubMed 29. Vakil N: Helicobacter pylori treatment: is sequential or quadruple therapy the answer? Rev Gastroenterol Disord 2008,8(2):77–82.PubMed 30. Matteo MJ, Granados G, Olmos M, Wonaga A, Catalano M: Helicobacter pylori amoxicillin heteroresistance due to point mutations Epacadostat mouse in PBP-1A in isogenic isolates. J Antimicrob Chemother 2008,61(3):474–477.CrossRefPubMed 31. Graham DY, Shiotani A: New concepts

of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008,5(6):321–331.CrossRefPubMed 32. Yang YH, Wu WK, Tai EK, Wong HP, Lam EK, So WH, Shin VY, Cho CH: The cationic host defense peptide rCRAMP promotes gastric ulcer healing in rats. J Pharmacol Exp Ther 2006,318(2):547–554.CrossRefPubMed 33. George LL, Borody TJ, Andrews P, Devine M, Defactinib order Moore-Jones D, Walton M, Brandl S: Cure of duodenal ulcer after eradication of

Helicobacter pylori. Med J Aust 1990,153(3):145–149.PubMed 34. Ding B, Guan Q, Walsh JP, Boswell JS, Winter TW, Winter ES, Boyd SS, Li C, Savage PB: Correlation of the check details antibacterial activities of cationic peptide antibiotics and cationic steroid antibiotics. J Med Chem 2002,45(3):663–669.CrossRefPubMed 35. Bucki R, Pastore JJ, Randhawa P, Vegners R, Weiner DJ, Janmey PA: Antibacterial activities of rhodamine B-conjugated gelsolin-derived peptides compared to those of the antimicrobial peptides cathelicidin

LL37, magainin II, and melittin. Antimicrob Agents Chemother 2004,48(5):1526–1533.CrossRefPubMed 36. Sheehan VM, Sleator RD, Hill C, Fitzgerald GF: Improving gastric transit, gastrointestinal persistence and therapeutic efficacy of the probiotic Silibinin strain Bifidobacterium breve UCC2003. Microbiology 2007,153(Pt 10):3563–3571.CrossRefPubMed 37. Gamble BM, Gallagher PA, Shoemaker JA, Parks AN, Freeman DM, Schwegel CA, Creed JT: An investigation of the chemical stability of arsenosugars in basic environments using IC-ICP-MS and IC-ESI-MS/MS. Analyst 2003,128(12):1458–1461.CrossRefPubMed Competing interests Dr P. Savage is a paid consultant for Ceragenix Pharmaceuticals, Innate Immune Inc., and WittyCell. None of the research reported in this paper was supported by Ceragenix Pharmaceuticals or by any other corporate entity. Other authors: none to declare. Authors’ contributions KL: carried out the H. pylori study, bacteria killing assay, performed the statistical analysis and drafted the manuscript; AN: carried out immunohistochemical studies; DF: carried out mass spectrometry; QW: participated in the H.